Education
About Us
Working with TipRanks
Follow Us
Bio-Path Holdings (BPTH)
OTHER OTC:BPTH
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-1.16Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: -5.56%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Positive
The call highlighted significant advancements in clinical trials and the expansion of the DNAbilize platform into new therapeutic areas, reflecting strong progress in drug development. Despite some financial challenges, such as increased administrative expenses and a decrease in cash position, the overall outlook remains positive due to substantial progress in pipeline advancements and research publications.Company Guidance
In the Bio-Path Holdings Q3 2024 earnings call, the company reported a net loss of $2.1 million, or $0.70 per share, which marks an improvement from the $3.2 million loss, or $6.36 per share, in the same period last year. Research and development expenses decreased to $1.3 million from $2.3 million, attributed to reduced manufacturing costs and clinical trial expenses. General and administrative expenses rose to $1.3 million from $1.0 million, driven by increased legal fees and salaries. The company's cash reserves stood at $0.6 million as of September 30, 2024, down from $1.1 million at the end of 2023, with $7.7 million net cash used in operating activities and $7.2 million generated from financing activities over the first nine months of 2024. Bio-Path is advancing its DNAbilize platform, aiming to expand into obesity and metabolic diseases while progressing clinical trials in oncology.Expansion of DNAbilize Platform
Initiation of clinical development program for BP-1001-A as a treatment for obesity and related metabolic diseases, marking the first non-cancer application of DNAbilize platform.
Progress in Cancer Treatment Trials
Continued advancement of Phase I/Ib clinical trials for BP1001-A in patients with solid tumors and BP1002 in refractory relapsed AML patients.
Publication and Potential of BP1003
Publication in Biomedicines journal highlighting the therapeutic potential of BP1003 in various cancer types, including breast, ovarian, and pancreatic cancer.
Financial Improvements
Net loss decreased to $2.1 million in Q3 2024 from $3.2 million in Q3 2023, with a decrease in research and development expenses.
Rapid Enrollment in Clinical Trials
Faster than projected enrollment for the third dosing cohort of 60 mg/m² in the BP1002 trial, completed within six weeks.
BPTH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BPTH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $0.18 | $0.18 | 0.00% |
Mar 28, 2025 | $0.17 | $0.16 | -5.88% |
Nov 15, 2024 | $0.90 | $0.81 | -10.00% |
Aug 15, 2024 | $1.51 | $1.49 | -1.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bio-Path Holdings (BPTH) report earnings?
Bio-Path Holdings (BPTH) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is Bio-Path Holdings (BPTH) earnings time?
Bio-Path Holdings (BPTH) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BPTH EPS forecast?
Currently, no data Available